CLINICAL LABORATORIES WITH A HIGH percentage of Medicare Part B lab test reimbursement are expected to suffer the most under the Part B Clinical Laboratory Fee Schedule (CLFS) cuts that the Centers for Medicare and Medicaid Services proposed Sept. 22.
With the proposed rates scheduled to go into effect on Jan. 1, that leaves just 12
ACROSS THE UNITED STATES, labs that perform pharmacogenomic tests complain that both government and private payers are reluctant to issue coverage guidelines and adequate reimbursement for these assays. Yet, this new class of diagnostic lab tests is the foundation of personalized and precision medicine.
Why are government and private health programs taking this tough stand on
CEO SUMMARY: Some in the lab industry had high hopes that passage of the Protecting Access to Medicare Act (PAMA) last year would favorably resolve a number of important issues. However, those hopes were dashed following the September 25 release by CMS of a proposed rule setting out how it will collect market test prices
BY NOW, MOST OF YOU HAVE LEARNED that, just 12 days ago, CMS issued the proposed rule that details how it will handle the private market price reporting mandate of the Protecting Access to Medicare Act of 2014 (PAMA). Almost immediately, critics spoke out about the obvious inequities that will result from implementing the proposed rule.
Cerner Corporation is celebrating a big sum- mer of contract awards from the Department of Defense. First up was a project to support further standardization of anatomic pathology within the laboratories operated worldwide by the DoD.
CEO SUMMARY: In a partnership with Walgreens pharmacies, Theranos Inc. announced that it will run clinical lab tests on “micro-samples” and collect these blood samples without venipuncture. Even as Theranos touts the patient-friendly benefits of its proprietary diagnostic technology, it has provided no information about the science that supports this testing and the clinical validations
Geisinger Health System broke ground last month on construction of a new $52 million medical laboratory facility. It will be 115,000 square feet and will be located at the site of the Geisinger Medical Center in Danville, Pennsylvania.
LAB COMPANY COMPLETES IPO
Cancer Genetics, Inc., of Rutherford, New Jersey, completed an initial public offering (IPO) and
CEO SUMMARY: BeaconLBS is a new business created by Laboratory Corporation of America. It says it wants to help health insurance plans manage molecular diagnostics and genetic testing. BeaconLBS is now recruiting other clinical labs to join its network and is meeting with payers to offer its lab test pre-authorization services. What may make BeaconLBS
IS THE TIMING of the criminal indictments of three ex-UroCor executives going to be a fortuitous event for the anatomic pathology profession?
I ask this question because the exploding trend of specialist physician groups internalizing anatomic pathology services was slated to be the sole topic for this and the next issue of THE DARK REPORT. Moreover,
CEO SUMMARY: Several recent acquisitions of lab test technology by billion-dollar diagnostics manufacturers reinforce a new reality in the healthcare marketplace: developing new diagnostic tests is faster, cheaper, and more profitable than developing new pharmaceutical products. This simple economic fact is driving an amazing expansion in the number of companies developing new lab test technology.